Since 2015, I have served as President of The Cure Alliance, a boutique 501(C)(3) non-profit with a mission to help research scientists accelerate the pace of their discoveries from the lab to the patient’s bedside.

In the very beginning, Dr. F. Charles Brunicardi spoke about the barriers he faced trying to cure pancreatic cancer, his professional dedication for decades. Pancreatic cancer has only an 8% survival rate, the lowest of any cancer in the U.S.

At the time, I published his story about the unnecessary, non-medical barriers on the road to curing pancreatic cancer.  Along with Dr. Camillo Ricordi, we began our mission at Capitol Hill where we FaceTimed Dr. Brunicardi into congressional offices to tell his story: 

During his tenure as the Michael E. DeBakey Chair of Surgery at Baylor College of Medicine in Houston, Texas, Dr. Brunicardi discovered a protein, PDX1, which was over-expressed in every tumor of the the most deadly form of pancreatic cancer.. (He would later discover a second such cancer-promoting protein, BIRC5Dr. Brunicardi and his team spent years testing various therapies on animals and finally discovered one therapy in particular successfully turned off the proteins and silenced pancreatic cancer. 

Frustratingly, he learned he had run into someone else’s relatively new technology patent. Although the patent was not being used to for any cancer applications, he was told its mere existence would effectively end his research fundingThat setback was harrowing.  But more determined than ever, Brunicardi and his team came up with  a surprising and innovative approach; they decided to plow through the FDA library of 2500 approved drugs, to see if any combination could turn off PDX1 and BIRC5.

Eureka. In the FDA’s own library, Dr. F. Charles Brunicardi and his team found three low-cost non-toxic widely-used generic oral drugs that, when combined, actually silence stage 4 metastatic pancreatic cancer.

Today, The Cure Alliance is excited to announce Dr. Brunicardi and his team are about to launch an FDA-authorized phase II clinical trial of their drug combination to end the deadliest form of pancreatic cancer. What’s more, their generic drugs combination works on the same mechanisms to silence glioblastoma, colorectal, prostate and triple-negative breast cancers. The FDA has already authorized expansion of the pilot study to include these other deadly cancers. 

This simple oral treatment has been developed as an alternative to the existing harsh and toxic and generally ineffective  chemotherapy protocols which are geared to extending life, often extending suffering.  Brunicardi’s treatment has been developed to halt cancer, not just slow it down.

Please press the DONATE button to help us raise $300k for this first in a series of most important clinical trials which will save millions of dollars and years of research with just three generic, non-toxic, low cost, oral medications ready to silence pancreatic cancer and more.

One hundred per cent of all donations will go directly to this clinical trial and it’s future expansion.. Of course, it’s tax-deductible.

Thank you,
Shelley Ross